Cleave Biosciences
Proteasome Inhibitor Platform

Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems. Cleave’s CB-5083 is a first-in-class, oral inhibitor of p97, a critical enzyme that controls various aspects of protein homeostasis. p97 inhibition has the potential to treat a wide range of cancers, including both solid tumors and hematologic malignancies.


University
California Institute of Technology
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website